Cognition Therapeutics, Inc. Q2 FY2023 earnings call

• Continued progress in clinical trials, with the SEQUEL trial showing CT1812 improved brain activity and connectivity via quantitative EEG in patients with mild to moderate Alzheimer’s disease. • Ongoing clinical trials include SHINE, START, and MAGNIFY; SEQUEL trial results were highlighted. • Scientific publications supporting the role of the sigma-2 receptor and disease modification through proteomic studies. • Received over $170 million in cumulative non-dilutive grant awards from institutions like the NIA, validating the scientific foundation.

No specific product segment financial performance details provided as the transcript does not break down results by product segments.

• Aim to fully enroll the SHINE trial by the end of 2023. • The START Phase 2 trial has activated its first clinical site. • Anticipate top line data from the SHINE trial by this time next year. • Estimated cash balance of $37.2 million as of June 30, 2023, is sufficient to fund operations and capital expenditures through the third quarter of 2024.

• Actual results could differ materially from forward-looking statements due to risks and uncertainties associated with the company’s business, as outlined in the Safe Harbor provisions of the Private Securities Litigation Reform Act.

Q: Concern on LEQEMBI approval impacting enrollment in SHINE and START trials A: No impact seen on SHINE enrollment; the commercial launch of LEQEMBI is a lengthy process and SHINE is expected to be fully enrolled by year-end. The START trial allows for individuals on antibody therapies with sufficient time on treatment Q: Feedback from KOLs on SEQUEL trial results A: Positive feedback on EEG results showing restored wave patterns to those of healthy adults, seen as a positive signal for future trials Q: Synergy between CT1812 and anti-amyloid antibodies and ARIA risk A: ApoE4 patients are in studies, but no differential response in ARIA to date; combination data will come from the START trial Q: Biomarkers for CT1812 and accelerated approval A: Looking at biomarkers like NFL, GFAP, and novel markers; conventional endpoints like ADAS-Cog 11 will be discussed with the FDA for approval Q: Dry AMD study timeline and financing A: Data from the dry AMD study will be available in 1.5 years; no current partnerships planned, but continuing to educate on the opportunity Q: Biomarkers vs EEG for CT1812 A: EEG was an exploratory study; conventional endpoints like ADAS-Cog 11 are anticipated for discussions with the FDA regarding regulatory approval